KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $63.3 million.

  • West Pharmaceutical Services' Capital Expenditures fell 2214.02% to $63.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.7 million, marking a year-over-year decrease of 1735.82%. This contributed to the annual value of $377.0 million for FY2024, which is 414.36% up from last year.
  • Per West Pharmaceutical Services' latest filing, its Capital Expenditures stood at $63.3 million for Q3 2025, which was down 2214.02% from $75.2 million recorded in Q2 2025.
  • West Pharmaceutical Services' 5-year Capital Expenditures high stood at $108.7 million for Q4 2023, and its period low was $54.7 million during Q1 2021.
  • Over the past 5 years, West Pharmaceutical Services' median Capital Expenditures value was $75.4 million (recorded in 2023), while the average stood at $78.3 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 7040.5% in 2021, then tumbled by 2495.01% in 2025.
  • Over the past 5 years, West Pharmaceutical Services' Capital Expenditures (Quarter) stood at $76.5 million in 2021, then increased by 24.05% to $94.9 million in 2022, then grew by 14.54% to $108.7 million in 2023, then fell by 3.5% to $104.9 million in 2024, then plummeted by 39.66% to $63.3 million in 2025.
  • Its Capital Expenditures was $63.3 million in Q3 2025, compared to $75.2 million in Q2 2025 and $71.3 million in Q1 2025.